Skip to main content
. 1998 Dec;72(12):9795–9805. doi: 10.1128/jvi.72.12.9795-9805.1998

TABLE 4.

Neutralization of an AAV vector by sera from B6 mice exposed to an AAV vector with or without CTLA4Ig and/or MR1 immunosuppressiona

Primary vector Treatment No. of animals Vector neutralization (%) for serum dilution indicatedb:
1:20 1:100
None (saline) None 3 0, 0, 0 0, 0, 0
AAV-βgal L6 + HIg 4 100, 100, 100, 100 100, 100, 100, 100
AAV-βgal MR1 + CTLA4Ig 4 0, 0, 0, 0 0, 0, 0, 0
AAV-βgal CTLA4Ig 4 100, 100, 4.7, 100 100, 50, 0, 100
AAV-βgal MR1 5 100, 100, 100, 100, 100 89, 38, 100, 100, 10
a

B6 mice were given saline or AAV-βgal (as described in Table 3) in the presence or absence of immunomodulating drugs. Fifty-four days later, serum samples were obtained and analyzed for neutralizing activity to AAV vector. 

b

Neutralization values for serum samples from individual animals are given in the same order for each serum dilution. 

HHS Vulnerability Disclosure